CRISPR/Cas9-based liver-derived reporter cells for screening of mPGES-1 inhibitors

References

• Radmark O, Samuelsson B. Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer. J Intern Med 2010;268:5–14.
   PubMed Web of Science ®Google Scholar
• Koeberle A, Werz O. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochem Pharmacol 2015;98:1–15.
   PubMed Web of Science ®Google Scholar
• El Mansouri FE, Nebbaki SS, Kapoor M, et al. Lysine-specific demethylase 1-mediated demethylation of histone H3 lysine 9 contributes to interleukin 1beta-induced microsomal prostaglandin E synthase 1 expression in human osteoarthritic chondrocytes. Arthritis Res Ther 2014;16:R113.
   PubMed Web of Science ®Google Scholar
• Kudo I, Murakami M. Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. J Biochem Mol Biol 2005;38:633–8.
   PubMedGoogle Scholar
• Sampey AV, Monrad S, Crofford LJ. Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2. Arthritis Res Ther 2005;7:114–7.
   PubMed Web of Science ®Google Scholar
• Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (New York, NY) 2001;294:1871–5.
   Google Scholar
• Ruan D, So SP. Prostaglandin E2 produced by inducible COX-2 and mPGES-1 promoting cancer cell proliferation in vitro and in vivo. Life Sci 2014;116:43–50.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet (London, England) 2005;365:475–81.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Investig 2006;116:1391–9.
   PubMed Web of Science ®Google Scholar
• Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 promotes hepatocarcinogenesis through activation of a novel EGR1/β-catenin signaling axis. Oncogene 2012;31:842–57.
   PubMed Web of Science ®Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science (New York, NY) 2014;346:1258096.
   Google Scholar
• Komor AC, Badran AH, Liu DR. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 2017;169:559.
   PubMed Web of Science ®Google Scholar
• Wang H, La Russa M, Qi LS. CRISPR/Cas9 in genome editing and beyond. Annu Rev Biochem 2016;85:227–64.
   PubMed Web of Science ®Google Scholar
• Rodrigues GMC, Gaj T, Adil MM, et al. Defined and scalable differentiation of human oligodendrocyte precursors from pluripotent stem cells in a 3D culture system. Stem Cell Rep 2017;8:1770–83.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Zhang T, Lacko LA, et al. Derivation and characterization of a UCP1 reporter human ES cell line. Stem Cell Res 2018;30:12–21.
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang L, Zhai J, et al. Generation of carbamoyl phosphate synthetase 1 reporter cell lines for the assessment of ammonia metabolism. J Cell Mol Med 2017;21:3214–23.
   PubMed Web of Science ®Google Scholar
• Baker O, Tsurkan S, Fu J, et al. The contribution of homology arms to nuclease-assisted genome engineering. Nucleic Acids Res 2017;45:8105–15.
   PubMed Web of Science ®Google Scholar
• Cho YS, Kim BS, Sim CK, et al. Establishment of IL-7 expression reporter human cell lines, and their feasibility for high-throughput screening of IL-7-upregulating chemicals. PLoS One 2016;11:e0161899.
   PubMed Web of Science ®Google Scholar
• Chen Z, Tang N, Wang X, Chen Y. The activity of the carbamoyl phosphate synthase 1 promoter in human liver-derived cells is dependent on hepatocyte nuclear factor 3-beta. J Cell Mol Med 2017;21:2036–45.
   PubMed Web of Science ®Google Scholar
• Lackner DH, Carre A, Guzzardo PM, et al. A generic strategy for CRISPR-Cas9-mediated gene tagging. Nat Commun 2015;6:10237.
   PubMed Web of Science ®Google Scholar
• Chari R, Mali P, Moosburner M, Church GM. Unraveling CRISPR-Cas9 genome engineering parameters via a library-on-library approach. Nat Methods 2015;12:823–6.
   PubMed Web of Science ®Google Scholar
• Bae S, Kweon J, Kim HS, Kim JS. Microhomology-based choice of Cas9 nuclease target sites. Nat Methods 2014;11:705–6.
   PubMed Web of Science ®Google Scholar
• Mali P, Yang L, Esvelt KM, et al. RNA-guided human genome engineering via Cas9. Science (New York, NY) 2013;339:823–6.
   Google Scholar
• Frock RL, Hu J, Meyers RM, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 2015;33:179–86.
   PubMed Web of Science ®Google Scholar
• Kosicki M, Tomberg K, Bradley A. Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol 2018;36:765–71.
   PubMed Web of Science ®Google Scholar
• Haapaniemi E, Botla S, Persson J, et al. CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response. Nat Med 2018;24:927–30.
   PubMed Web of Science ®Google Scholar
• Ihry RJ, Worringer KA, Salick MR, et al. p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells. Nat Med 2018;24:939–46.
   PubMed Web of Science ®Google Scholar
• Nishizawa N, Ito Y, Eshima K, et al. Inhibition of microsomal prostaglandin E synthase-1 facilitates liver repair after hepatic injury in mice. J Hepatol 2018;69:110–20.
   PubMed Web of Science ®Google Scholar
• Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology 2011;140:2084–94.
   PubMed Web of Science ®Google Scholar
• Kock A, Larsson K, Bergqvist F, et al. Inhibition of microsomal prostaglandin E synthase-1 in cancer-associated fibroblasts suppresses neuroblastoma tumor growth. EBioMedicine 2018;32:84–92.
   PubMed Web of Science ®Google Scholar
• Larsson K, Kock A, Idborg H, et al. COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci USA 2015;112:8070–5.
   PubMed Web of Science ®Google Scholar
• Coulombe F, Jaworska J, Verway M, et al. Targeted prostaglandin E2 inhibition enhances antiviral immunity through induction of type I interferon and apoptosis in macrophages. Immunity 2014;40:554–68.
   PubMed Web of Science ®Google Scholar
• Bahia MS, Katare YK, Silakari O, et al. Inhibitors of microsomal prostaglandin E2 synthase-1 enzyme as emerging anti-inflammatory candidates. Med Res Rev 2014;34:825–55.
   PubMed Web of Science ®Google Scholar
• Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev 2007;59:207–24.
   PubMed Web of Science ®Google Scholar